Erwin Astha Triyono and Juniastuti and Muhammad Vitanata Arfijanto and Pratama EM (2019) Profile of Antiretroviral Resistance in HIV/AIDS Patients in Dr. Soetomo General Academic Hospital Surabaya. New Armenian Medical Journal, 13 (4). pp. 77-84. ISSN 18290825

	Text (Artikel) Profile of Antiretroviral resistance in HIVAIDS patients in Dr. Soetomo General Academic Hospital Surabaya.pdf Download (256kB)
	Text (Peer Review) Profile of Antiretroviral.pdf Download (3MB)
	Text (Similarity) Profile of Antiretroviral resistance in HIVAIDS patients in Dr. Soetomo General Academic Hospital Surabaya.pdf Download (2MB)

Abstract

Background: World HIV/AIDS prevalences reach to 36,9 million patient. Most patient located in Africa as much as 24,7 million. Meanwhile in Asia, 4,8 million people recorded suffered from HIV/AIDS. The first time HIV/AIDS was reported in Indonesia in 1987. The prevalence of HIV/AIDS in Indonesia since it first discovered until 2016 was spread in 80% districs/cities from all provinces in Indonesia. Dr. Soetomo general hospital is a referral hospital in the eastern part of Indonesia. It has HIV care unit which many HIV/AIDS patients were treated with antiretroviral. However, the data of profile of antiretroviral resistance is still limited. Objective: This study aimed to identify the profile of antiretroviral resistance in patients treated with antiretroviral in Dr. Soetomo hospital in Surabaya. Methods: This study used descriptive retrospective design. The data of antiretroviral resistance was obtained from treated patients by using medical record. The examined population was all patient diagnosed with HIV/AIDS in Dr. Soetomo Hospital Surabaya. Results: Combination of Lamivudine, Zidovudine and Nevirapine of the first line antiretroviral was most often used (70.6%) to treat the patients. The highest drug resistance was found in Nevirapine and Efavirenz (members of Non-nucleoside reverce transcriptase inhibitors) (58.8%, respectively) with the associated mutation patterns of HIV polymerase included Y181C, V108I, V106I, G190GA (~ Nevirapine resistance) and Y181C, V108I, V106I (~ Efavirenz resistance); while the most resistant members of nucleoside reverce transcriptase inhibitors were Lamivudine and Emtricitabine (23.5%, respectively) (M184V and K65R), followed by Tenofovir (17.6%) (K65R) and Zidovudine (5.9%) (K219QE). Conclusion: Most patients showed high resistance to Nevirapine and Efavirenz in non-nucleoside reverce transcriptase inhibitors group, followed by Lamivudine and Emtricitabine in nucleoside reverce transcriptase inhibitors group.

Actions (login required)

View Item